查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2151723

非碘基X光造影劑市場：全球市場預測（2026-2032年）

Non-iodinated X-ray Contrast Agents Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，非碘基 X 光造影劑市場將成長至 50.8 億美元，複合年成長率為 9.64%。

主要市場統計數據
基準年 2025 26.6億美元
預計年份：2026年 28.7億美元
預測年份 2032 50.8億美元
複合年成長率 (%) 9.64%

非碘基X光造影劑：概述

非碘基X光造影劑為尋求傳統碘基造影劑替代方案的臨床醫生提供了支持，也適用於需要特定對比特性的診斷成像應用。其重要性取決於患者的特定安全考慮、影像性能、監管要求、檢查量以及輔助成像方法的可用性。是否採用此類造影劑通常並非取決於單一的技術特性，而是綜合考慮臨床證據、工作流程相容性、供應可靠性以及整體治療成本效益。

臨床個體化和影像診斷工作流程正在改變這些技術的實施方式。

由於人們對個人化影像方案、腎功能和超敏反應風險評估、輻射防護意識增強以及對更高效診斷流程的需求日益成長，影像產業的格局正在改變。醫院和影像服務提供者也更加重視與最新掃描器的互通性、標準化的操作流程、員工培訓和品質保證。這些變化促使人們傾向於選擇那些擁有可靠臨床數據支援、標籤清晰、物流可靠且能夠融入日常工作流程而不增加不必要複雜性的產品。

人工智慧可以改善藥物選擇、方案設計和品管。

人工智慧 (AI) 主要透過影像重建、方案最佳化、自動分診和決策支援等方式影響著這一領域。 AI 系統能夠幫助臨床醫生最佳化檢測參數、識別技術上不恰當的檢測項目並確定後續追蹤的優先順序。同時，機器學習工具可以幫助不同操作者和機構保持檢測結果的一致性。然而，AI 並不能取代對比劑性能的檢驗、臨床監督、透明的數據管治、網路安全措施以及對偏差和診斷可靠性的前瞻性評估。

區域洞察：監管、基礎設施與准入塑造市場格局

在北美，先進的影像基礎設施以及嚴格的監管和醫療保健系統要求，正推動實證醫學的採納和整合到工作流程中。在歐洲，人們高度重視統一的安全標準、採購規範和跨境監管協調。亞太地區呈現出多元化的格局，既有高度發展的影像系統，也有快速擴張的醫療服務覆蓋範圍，以及專科醫師能力上的差異。拉丁美洲受到多種因素的影響，例如對進口的依賴、多樣化的報銷機制以及先進服務集中在主要大都市地區。在中東，對專業醫療保健基礎設施的投資正在推進，同時人力資源發展和供應韌性也受到重視。非洲的情況仍然高度複雜，醫療保健服務的可近性取決於設備可用性、資金籌措、維護能力以及診斷人員短缺等因素。

集團洞察：生態系統和聯盟正在形成清晰的業務優先事項。

在東協市場，監管成熟度、醫療保健資金籌措以及對進口診斷影像耗材的依賴程度各不相同，因此區域報名手續和分銷商能力至關重要。在金磚國家，除了龐大且多元化的醫療保健系統外，各國也越來越關注國內醫療能力、可負擔性和技術普及性。歐盟強調監管協調、病人安全、採購透明度和跨境標準。七國集團（G7）的醫療保健系統普遍優先考慮先進的臨床證據、品管以及與複雜診療路徑的整合。海灣合作理事會（GCC）國家正在加強三級醫療和診斷基礎設施建設，同時也尋求可靠的供應和專業知識。北約成員國儘管醫療保健系統形式各異，但都對醫療系統的韌性、醫療服務的連續性和安全的數位基礎設施共用的關注。

國家概況：各國醫療保健系統如何影響用例

澳洲和加拿大優先考慮集中式或區域協調的採購、臨床管治以及為地域分散的人群提供醫療服務。美國的特點是複雜的報銷系統、醫院採購、監管以及先進影像技術的應用。巴西和墨西哥面臨區域差異、進口和分銷挑戰以及公立和私立醫療機構之間的服務取得差距。中國和印度雖然擁有龐大的病患群體，但在醫院容量水準、國內製造業發展以及都市區醫療服務取得方面存在差異。日本、韓國、法國、德國、義大利、西班牙和英國擁有成熟的影像生態系統，但其具體實施方式因各國在報銷規則、採購結構、臨床指南和醫療技術評估方面的做法而異。俄羅斯的醫療環境受到醫療現代化、供應鏈韌性以及監管和准入條件等因素的影響。

領導階層優先事項：透過證據、韌性和工作流程創造價值。

行業領導者應優先考慮為相關患者群體和檢測類型建立臨床可靠的證據，同時保持清晰的安全資訊傳播和嚴格的上市後監測。產品開發應著重考慮與現代影像工作流程的兼容性、實際操作性、儲存和培訓要求。各組織應透過多元化關鍵資源投入、確保替代物流路線和加強品管系統來降低業務中斷的風險。負責任的人工智慧部署需要檢驗的效能、人工審核、網路安全和透明的管治。區域策略應根據報銷、法規、基礎設施和人力資源的實際情況進行調整，而不是簡單地照搬跨地域的現有策略。

調查方法：對檢驗的市場證據進行結構化整合

本執行摘要基於非碘基X光造影劑的既定市場範圍，按技術、臨床工作流程、監管、基礎設施、區域和醫療保健系統特徵對研究結果進行分類。本分析區分了已記錄的行業現狀和主觀解讀，避免了未經證實的數字聲明，並且不提及估計值、預測、市場佔有率和公司定位等資訊。區域、群體和國家層面的觀察結果僅作為背景資訊提供，在製定策略決策之前，應根據當前的監管文件、臨床指南、採購記錄、同行評審的證據和醫療保健系統數據檢驗。

結論：循證整合是實現永續進步的關鍵。

非碘基X光造影劑的未來取決於它們能否在日益個性化、數位化和資源高效的診斷成像系統中提供具有臨床意義的價值。可靠的安全證據、穩定的供應鏈、合規的監管以及無縫的工作流程整合是成功應用的關鍵。那些將系統性的證據產生與區域性部署、負責任的人工智慧實踐和穩健的營運模式相結合的領導企業，將更有能力滿足不斷變化的診斷需求，同時確保病患安全和醫療品質。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 非碘基X光造影劑市場：依產品類型分類

  • 鋇造影劑
    • 標準密度鋇懸浮液
    • 高密度鋇懸浮液
    • 鋇灌腸製劑
  • 用於X光的钆對比劑
    • 血管內钆造影劑
    • 用於關節內注射的钆對比劑
  • 氣體造影劑
    • 二氧化碳造影劑
    • 室內空氣對比劑
  • 非碘奈米顆粒造影劑
    • 金屬基奈米顆粒造影劑
    • 聚合物奈米顆粒造影劑

第8章 非碘基X光造影劑市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 直腸給藥

第9章 非碘基X光造影劑市場：依配方分類

  • 粉末
  • 懸浮液

第10章 非碘基X光造影劑市場：依應用領域分類

  • 血管造影術
    • 腦動脈
    • 冠狀動脈
    • 周邊動脈
  • 消化器官系統成像
    • 下消化道
    • 上消化道

第11章 非碘基X光造影劑市場：依最終用戶分類

  • 門診治療
    • 診斷影像中心
    • 門診部
  • 診斷中心
  • 醫院
    • 私立醫院
    • 公立醫院

第12章 非碘基X光造影劑市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 非碘基X光造影劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 非碘基X光造影劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Bayer AG
  • Beijing Beilu Pharmaceutical Co., Ltd.
  • Bracco Imaging SpA
  • CMC Contrast AB
  • Fresenius Kabi AG
  • FUJIFILM Corporation
  • GE HealthCare Technologies Inc.
  • Guerbet
  • IMAX Diagnostic Imaging Limited
  • JB Chemicals & Pharmaceuticals Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Lantheus Holdings, Inc.
  • Merck KGaA
  • Nano Therapeutics Pvt. Ltd.
  • Spago Nanomedical AB
  • Taejoon Pharm Co., Ltd.
  • Trivitron Healthcare Pvt. Ltd.

第17章 主要專家

Product Code: MRR-537DB9F44B30

The Non-iodinated X-ray Contrast Agents Market is projected to grow by USD 5.08 billion at a CAGR of 9.64% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.66 billion
Estimated Year [2026] USD 2.87 billion
Forecast Year [2032] USD 5.08 billion
CAGR (%) 9.64%

Non-Iodinated X-Ray Contrast Agents: Executive Overview

Non-iodinated X-ray contrast agents support diagnostic imaging applications where clinicians seek alternatives to conventional iodinated media or require specialized contrast behavior. Their relevance is shaped by patient-specific safety considerations, imaging performance, regulatory requirements, procedure volumes, and the availability of complementary modalities. Adoption decisions typically depend on clinical evidence, workflow compatibility, supply reliability, and total treatment economics rather than on a single technical attribute.

Clinical Personalization and Imaging Workflow Are Reshaping Adoption

The landscape is being transformed by greater attention to individualized imaging protocols, renal and hypersensitivity risk assessment, radiation-conscious care, and demand for more efficient diagnostic pathways. Hospitals and imaging providers are also emphasizing interoperability with modern scanners, standardized administration procedures, staff training, and quality assurance. These shifts favor products supported by robust clinical documentation, clear labeling, dependable logistics, and evidence that they can integrate into routine workflows without adding avoidable complexity.

Artificial Intelligence Elevates Selection, Protocol Design, and Quality Control

Artificial intelligence is influencing this field primarily through image reconstruction, protocol optimization, automated triage, and decision support. AI-enabled systems can help clinicians tailor examination parameters, identify technically inadequate studies, and prioritize follow-up, while machine-learning tools may support consistency across operators and sites. However, AI does not remove the need for validated contrast-agent performance, clinical oversight, transparent data governance, cybersecurity controls, and prospective assessment of bias and diagnostic reliability.

Regional Insights: Regulation, Infrastructure, and Access Shape Market Conditions

North America combines advanced imaging infrastructure with stringent regulatory and health-system requirements, encouraging evidence-led adoption and workflow integration. Europe places strong emphasis on harmonized safety standards, procurement discipline, and cross-border regulatory alignment. Asia-Pacific presents varied conditions, ranging from highly developed imaging systems to rapidly expanding access and uneven specialist capacity. Latin America is influenced by import dependence, reimbursement diversity, and concentration of advanced services in major urban centers. The Middle East is investing in specialized healthcare infrastructure while prioritizing workforce development and supply resilience. Africa remains highly heterogeneous, with access shaped by equipment availability, financing, maintenance capability, and diagnostic workforce constraints.

Group Insights: Economic Blocs and Alliances Create Distinct Operating Priorities

ASEAN markets reflect varied regulatory maturity, healthcare financing, and dependence on imported imaging supplies, making regional registration and distributor capability important. BRICS economies combine large and diverse healthcare systems with growing interest in domestic capacity, affordability, and technology access. The European Union emphasizes coordinated regulation, patient safety, procurement transparency, and cross-border standards. G7 systems generally prioritize advanced clinical evidence, quality management, and integration into sophisticated care pathways. GCC countries are strengthening tertiary and diagnostic infrastructure while seeking reliable supply and specialized expertise. NATO members span different health systems but share interest in resilience, continuity of medical supply, and secure digital infrastructure.

Country Insights: National Health-System Conditions Influence Use Cases

Australia and Canada emphasize centralized or regionally coordinated procurement, clinical governance, and access across geographically dispersed populations. The United States is shaped by complex reimbursement, hospital purchasing, regulatory scrutiny, and advanced imaging utilization. Brazil and Mexico face regional disparities, import and distribution considerations, and uneven access between private and public providers. China and India combine large patient populations with differing levels of hospital capability, domestic manufacturing development, and urban-rural access. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom have mature imaging ecosystems, but adoption is differentiated by reimbursement rules, procurement structures, clinical guidelines, and national approaches to health technology assessment. Russia's environment is influenced by healthcare modernization needs, supply-chain resilience, and regulatory and access conditions.

Priorities for Leaders: Build Evidence, Resilience, and Workflow Value

Industry leaders should prioritize clinically credible evidence for relevant patient groups and examination types, while maintaining clear safety communication and disciplined post-market monitoring. Product development should focus on compatibility with contemporary imaging workflows, practical administration, storage, and training requirements. Organizations should diversify critical inputs, qualify alternative logistics routes, and strengthen quality systems to reduce disruption risk. Responsible AI deployment requires validated performance, human review, cybersecurity, and transparent governance. Regional strategies should be adapted to reimbursement, regulatory, infrastructure, and workforce realities rather than copied across geographies.

Research Methodology: Structured Synthesis of Verified Market Evidence

This executive summary uses the defined market scope of non-iodinated X-ray contrast agents and organizes findings across technology, clinical workflow, regulation, infrastructure, geography, and healthcare-system characteristics. The analysis distinguishes documented industry conditions from interpretation, excludes unsupported numerical claims, and avoids estimates, forecasts, market shares, and company-specific positioning. Regional, group, and country observations are presented as contextual insights requiring validation against current regulatory publications, clinical guidance, procurement records, peer-reviewed evidence, and health-system data before strategic decisions are made.

Conclusion: Evidence-Led Integration Will Define Sustainable Progress

The trajectory of non-iodinated X-ray contrast agents will depend on their ability to deliver clinically meaningful value within increasingly personalized, digitally enabled, and resource-conscious imaging systems. Strong safety evidence, dependable supply, regulatory alignment, and seamless workflow integration are central to adoption. Leaders that combine disciplined evidence generation with region-specific implementation, responsible AI practices, and resilient operating models will be better positioned to address evolving diagnostic needs without compromising patient protection or care quality.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Non-iodinated X-ray Contrast Agents Market, by Product Type

  • 7.1. Introduction
  • 7.2. Barium Contrast Media
    • 7.2.1. Standard-density Barium Suspensions
    • 7.2.2. High-density Barium Suspensions
    • 7.2.3. Barium Enema Formulations
  • 7.3. Gadolinium Contrast Media For X-ray
    • 7.3.1. Intravascular Gadolinium Agents
    • 7.3.2. Intra-articular Gadolinium Agents
  • 7.4. Gas Contrast Media
    • 7.4.1. Carbon Dioxide Contrast Media
    • 7.4.2. Room Air Contrast Media
  • 7.5. Non-iodinated Nanoparticle Contrast Media
    • 7.5.1. Metal-based Nanoparticle Agents
    • 7.5.2. Polymer-based Nanoparticle Agents

8. Non-iodinated X-ray Contrast Agents Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Rectal

9. Non-iodinated X-ray Contrast Agents Market, by Formulation

  • 9.1. Introduction
  • 9.2. Powder
  • 9.3. Suspension

10. Non-iodinated X-ray Contrast Agents Market, by Application

  • 10.1. Introduction
  • 10.2. Angiography
    • 10.2.1. Cerebral Artery
    • 10.2.2. Coronary Artery
    • 10.2.3. Peripheral Artery
  • 10.3. Gastrointestinal Imaging
    • 10.3.1. Lower Gastrointestinal
    • 10.3.2. Upper Gastrointestinal

11. Non-iodinated X-ray Contrast Agents Market, by End User

  • 11.1. Introduction
  • 11.2. Ambulatory Care
    • 11.2.1. Imaging Centers
    • 11.2.2. Outpatient Clinics
  • 11.3. Diagnostic Centers
  • 11.4. Hospitals
    • 11.4.1. Private Hospitals
    • 11.4.2. Public Hospitals

12. Non-iodinated X-ray Contrast Agents Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Non-iodinated X-ray Contrast Agents Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Non-iodinated X-ray Contrast Agents Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Bayer AG
  • 16.2. Beijing Beilu Pharmaceutical Co., Ltd.
  • 16.3. Bracco Imaging S.p.A.
  • 16.4. CMC Contrast AB
  • 16.5. Fresenius Kabi AG
  • 16.6. FUJIFILM Corporation
  • 16.7. GE HealthCare Technologies Inc.
  • 16.8. Guerbet
  • 16.9. IMAX Diagnostic Imaging Limited
  • 16.10. J.B. Chemicals & Pharmaceuticals Ltd.
  • 16.11. Jiangsu Hengrui Medicine Co., Ltd.
  • 16.12. Lantheus Holdings, Inc.
  • 16.13. Merck KGaA
  • 16.14. Nano Therapeutics Pvt. Ltd.
  • 16.15. Spago Nanomedical AB
  • 16.16. Taejoon Pharm Co., Ltd.
  • 16.17. Trivitron Healthcare Pvt. Ltd.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Non-iodinated X-ray Contrast Agents Market, Years Considered for the Study
  • FIGURE 2. Global Non-iodinated X-ray Contrast Agents Market, Research Design
  • FIGURE 3. Global Non-iodinated X-ray Contrast Agents Market, Research Framework
  • FIGURE 4. Global Non-iodinated X-ray Contrast Agents Market, Data Triangulation
  • FIGURE 5. Global Non-iodinated X-ray Contrast Agents Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 9. Global Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2025 vs 2032 (%)
  • FIGURE 11. Global Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Non-iodinated X-ray Contrast Agents Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 13. Global Non-iodinated X-ray Contrast Agents Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Non-iodinated X-ray Contrast Agents Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global Non-iodinated X-ray Contrast Agents Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Non-iodinated X-ray Contrast Agents Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Non-iodinated X-ray Contrast Agents Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Non-iodinated X-ray Contrast Agents Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Non-iodinated X-ray Contrast Agents Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Non-iodinated X-ray Contrast Agents Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Non-iodinated X-ray Contrast Agents Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Non-iodinated X-ray Contrast Agents Market Segmentation & Coverage
  • TABLE 2. Global Non-iodinated X-ray Contrast Agents Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global Barium Contrast Media Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Barium Contrast Media Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Barium Contrast Media Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Standard-density Barium Suspensions Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Standard-density Barium Suspensions Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Standard-density Barium Suspensions Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global High-density Barium Suspensions Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global High-density Barium Suspensions Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global High-density Barium Suspensions Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Barium Enema Formulations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Barium Enema Formulations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Barium Enema Formulations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Gadolinium Contrast Media For X-ray Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Gadolinium Contrast Media For X-ray Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Gadolinium Contrast Media For X-ray Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Intravascular Gadolinium Agents Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Intravascular Gadolinium Agents Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Intravascular Gadolinium Agents Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Intra-articular Gadolinium Agents Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Intra-articular Gadolinium Agents Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Intra-articular Gadolinium Agents Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Gas Contrast Media Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Gas Contrast Media Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Gas Contrast Media Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Carbon Dioxide Contrast Media Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Carbon Dioxide Contrast Media Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Carbon Dioxide Contrast Media Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Room Air Contrast Media Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Room Air Contrast Media Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Room Air Contrast Media Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Non-iodinated Nanoparticle Contrast Media Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Non-iodinated Nanoparticle Contrast Media Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Non-iodinated Nanoparticle Contrast Media Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Metal-based Nanoparticle Agents Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Metal-based Nanoparticle Agents Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Metal-based Nanoparticle Agents Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Polymer-based Nanoparticle Agents Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Polymer-based Nanoparticle Agents Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Polymer-based Nanoparticle Agents Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 44. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Oral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Global Oral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 49. Global Oral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 50. Global Rectal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Rectal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Rectal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 54. Global Powder Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. Global Powder Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 56. Global Powder Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 57. Global Suspension Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. Global Suspension Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 59. Global Suspension Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 60. Global Non-iodinated X-ray Contrast Agents Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 61. Global Angiography Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Angiography Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Angiography Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Cerebral Artery Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Cerebral Artery Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Cerebral Artery Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global Coronary Artery Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global Coronary Artery Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global Coronary Artery Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global Peripheral Artery Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 71. Global Peripheral Artery Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 72. Global Peripheral Artery Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 73. Global Gastrointestinal Imaging Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. Global Gastrointestinal Imaging Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 75. Global Gastrointestinal Imaging Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 76. Global Lower Gastrointestinal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 77. Global Lower Gastrointestinal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 78. Global Lower Gastrointestinal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 79. Global Upper Gastrointestinal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. Global Upper Gastrointestinal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 81. Global Upper Gastrointestinal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 82. Global Non-iodinated X-ray Contrast Agents Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 83. Global Ambulatory Care Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Global Ambulatory Care Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. Global Ambulatory Care Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 86. Global Imaging Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Global Imaging Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 88. Global Imaging Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 89. Global Outpatient Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 90. Global Outpatient Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 91. Global Outpatient Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 92. Global Diagnostic Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 93. Global Diagnostic Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 94. Global Diagnostic Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 95. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 96. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 97. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 98. Global Private Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 99. Global Private Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 100. Global Private Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 101. Global Public Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 102. Global Public Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 103. Global Public Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 104. Global Non-iodinated X-ray Contrast Agents Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 105. Asia-Pacific Non-iodinated X-ray Contrast Agents Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 106. Asia-Pacific Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 107. Asia-Pacific Non-iodinated X-ray Contrast Agents Market Size, by Barium Contrast Media, 2017-2032 (USD Million)
  • TABLE 108. Asia-Pacific Non-iodinated X-ray Contrast Agents Market Size, by Gadolinium Contrast Media For X-ray, 2017-2032 (USD Million)
  • TABLE 109. Asia-Pacific Non-iodinated X-ray Contrast Agents Market Size, by Gas Contrast Media, 2017-2032 (USD Million)
  • TABLE 110. Asia-Pacific Non-iodinated X-ray Contrast Agents Market Size, by Non-iodinated Nanoparticle Contrast Media, 2017-2032 (USD Million)
  • TABLE 111. Asia-Pacific Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 112. Asia-Pacific Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 113. Asia-Pacific Non-iodinated X-ray Contrast Agents Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 114. Asia-Pacific Non-iodinated X-ray Contrast Agents Market Size, by Angiography, 2017-2032 (USD Million)
  • TABLE 115. Asia-Pacific Non-iodinated X-ray Contrast Agents Market Size, by Gastrointestinal Imaging, 2017-2032 (USD Million)
  • TABLE 116. Asia-Pacific Non-iodinated X-ray Contrast Agents Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 117. Asia-Pacific Non-iodinated X-ray Contrast Agents Market Size, by Ambulatory Care, 2017-2032 (USD Million)
  • TABLE 118. Asia-Pacific Non-iodinated X-ray Contrast Agents Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 119. North America Non-iodinated X-ray Contrast Agents Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 120. North America Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 121. North America Non-iodinated X-ray Contrast Agents Market Size, by Barium Contrast Media, 2017-2032 (USD Million)
  • TABLE 122. North America Non-iodinated X-ray Contrast Agents Market Size, by Gadolinium Contrast Media For X-ray, 2017-2032 (USD Million)
  • TABLE 123. North America Non-iodinated X-ray Contrast Agents Market Size, by Gas Contrast Media, 2017-2032 (USD Million)
  • TABLE 124. North America Non-iodinated X-ray Contrast Agents Market Size, by Non-iodinated Nanoparticle Contrast Media, 2017-2032 (USD Million)
  • TABLE 125. North America Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 126. North America Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 127. North America Non-iodinated X-ray Contrast Agents Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 128. North America Non-iodinated X-ray Contrast Agents Market Size, by Angiography, 2017-2032 (USD Million)
  • TABLE 129. North America Non-iodinated X-ray Contrast Agents Market Size, by Gastrointestinal Imaging, 2017-2032 (USD Million)
  • TABLE 130. North America Non-iodinated X-ray Contrast Agents Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 131. North America Non-iodinated X-ray Contrast Agents Market Size, by Ambulatory Care, 2017-2032 (USD Million)
  • TABLE 132. North America Non-iodinated X-ray Contrast Agents Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 133. Latin America Non-iodinated X-ray Contrast Agents Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 134. Latin America Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 135. Latin America Non-iodinated X-ray Contrast Agents Market Size, by Barium Contrast Media, 2017-2032 (USD Million)
  • TABLE 136. Latin America Non-iodinated X-ray Contrast Agents Market Size, by Gadolinium Contrast Media For X-ray, 2017-2032 (USD Million)
  • TABLE 137. Latin America Non-iodinated X-ray Contrast Agents Market Size, by Gas Contrast Media, 2017-2032 (USD Million)
  • TABLE 138. Latin America Non-iodinated X-ray Contrast Agents Market Size, by Non-iodinated Nanoparticle Contrast Media, 2017-2032 (USD Million)
  • TABLE 139. Latin America Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 140. Latin America Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 141. Latin America Non-iodinated X-ray Contrast Agents Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 142. Latin America Non-iodinated X-ray Contrast Agents Market Size, by Angiography, 2017-2032 (USD Million)
  • TABLE 143. Latin America Non-iodinated X-ray Contrast Agents Market Size, by Gastrointestinal Imaging, 2017-2032 (USD Million)
  • TABLE 144. Latin America Non-iodinated X-ray Contrast Agents Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 145. Latin America Non-iodinated X-ray Contrast Agents Market Size, by Ambulatory Care, 2017-2032 (USD Million)
  • TABLE 146. Latin America Non-iodinated X-ray Contrast Agents Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 147. Europe Non-iodinated X-ray Contrast Agents Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 148. Europe Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 149. Europe Non-iodinated X-ray Contrast Agents Market Size, by Barium Contrast Media, 2017-2032 (USD Million)
  • TABLE 150. Europe Non-iodinated X-ray Contrast Agents Market Size, by Gadolinium Contrast Media For X-ray, 2017-2032 (USD Million)
  • TABLE 151. Europe Non-iodinated X-ray Contrast Agents Market Size, by Gas Contrast Media, 2017-2032 (USD Million)
  • TABLE 152. Europe Non-iodinated X-ray Contrast Agents Market Size, by Non-iodinated Nanoparticle Contrast Media, 2017-2032 (USD Million)
  • TABLE 153. Europe Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 154. Europe Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 155. Europe Non-iodinated X-ray Contrast Agents Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 156. Europe Non-iodinated X-ray Contrast Agents Market Size, by Angiography, 2017-2032 (USD Million)
  • TABLE 157. Europe Non-iodinated X-ray Contrast Agents Market Size, by Gastrointestinal Imaging, 2017-2032 (USD Million)
  • TABLE 158. Europe Non-iodinated X-ray Contrast Agents Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 159. Europe Non-iodinated X-ray Contrast Agents Market Size, by Ambulatory Care, 2017-2032 (USD Million)
  • TABLE 160. Europe Non-iodinated X-ray Contrast Agents Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 161. Middle East Non-iodinated X-ray Contrast Agents Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 162. Middle East Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 163. Middle East Non-iodinated X-ray Contrast Agents Market Size, by Barium Contrast Media, 2017-2032 (USD Million)
  • TABLE 164. Middle East Non-iodinated X-ray Contrast Agents Market Size, by Gadolinium Contrast Media For X-ray, 2017-2032 (USD Million)
  • TABLE 165. Middle East Non-iodinated X-ray Contrast Agents Market Size, by Gas Contrast Media, 2017-2032 (USD Million)
  • TABLE 166. Middle East Non-iodinated X-ray Contrast Agents Market Size, by Non-iodinated Nanoparticle Contrast Media, 2017-2032 (USD Million)
  • TABLE 167. Middle East Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 168. Middle East Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 169. Middle East Non-iodinated X-ray Contrast Agents Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 170. Middle East Non-iodinated X-ray Contrast Agents Market Size, by Angiography, 2017-2032 (USD Million)
  • TABLE 171. Middle East Non-iodinated X-ray Contrast Agents Market Size, by Gastrointestinal Imaging, 2017-2032 (USD Million)
  • TABLE 172. Middle East Non-iodinated X-ray Contrast Agents Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 173. Middle East Non-iodinated X-ray Contrast Agents Market Size, by Ambulatory Care, 2017-2032 (USD Million)
  • TABLE 174. Middle East Non-iodinated X-ray Contrast Agents Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 175. Africa Non-iodinated X-ray Contrast Agents Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 176. Africa Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 177. Africa Non-iodinated X-ray Contrast Agents Market Size, by Barium Contrast Media, 2017-2032 (USD Million)
  • TABLE 178. Africa Non-iodinated X-ray Contrast Agents Market Size, by Gadolinium Contrast Media For X-ray, 2017-2032 (USD Million)
  • TABLE 179. Africa Non-iodinated X-ray Contrast Agents Market Size, by Gas Contrast Media, 2017-2032 (USD Million)
  • TABLE 180. Africa Non-iodinated X-ray Contrast Agents Market Size, by Non-iodinated Nanoparticle Contrast Media, 2017-2032 (USD Million)
  • TABLE 181. Africa Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 182. Africa Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 183. Africa Non-iodinated X-ray Contrast Agents Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 184. Africa Non-iodinated X-ray Contrast Agents Market Size, by Angiography, 2017-2032 (USD Million)
  • TABLE 185. Africa Non-iodinated X-ray Contrast Agents Market Size, by Gastrointestinal Imaging, 2017-2032 (USD Million)
  • TABLE 186. Africa Non-iodinated X-ray Contrast Agents Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 187. Africa Non-iodinated X-ray Contrast Agents Market Size, by Ambulatory Care, 2017-2032 (USD Million)
  • TABLE 188. Africa Non-iodinated X-ray Contrast Agents Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 189. Global Non-iodinated X-ray Contrast Agents Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 190. ASEAN Non-iodinated X-ray Contrast Agents Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 191. ASEAN Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 192. ASEAN Non-iodinated X-ray Contrast Agents Market Size, by Barium Contrast Media, 2017-2032 (USD Million)
  • TABLE 193. ASEAN Non-iodinated X-ray Contrast Agents Market Size, by Gadolinium Contrast Media For X-ray, 2017-2032 (USD Million)
  • TABLE 194. ASEAN Non-iodinated X-ray Contrast Agents Market Size, by Gas Contrast Media, 2017-2032 (USD Million)
  • TABLE 195. ASEAN Non-iodinated X-ray Contrast Agents Market Size, by Non-iodinated Nanoparticle Contrast Media, 2017-2032 (USD Million)
  • TABLE 196. ASEAN Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 197. ASEAN Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 198. ASEAN Non-iodinated X-ray Contrast Agents Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 199. ASEAN Non-iodinated X-ray Contrast Agents Market Size, by Angiography, 2017-2032 (USD Million)
  • TABLE 200. ASEAN Non-iodinated X-ray Contrast Agents Market Size, by Gastrointestinal Imaging, 2017-2032 (USD Million)
  • TABLE 201. ASEAN Non-iodinated X-ray Contrast Agents Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 202. ASEAN Non-iodinated X-ray Contrast Agents Market Size, by Ambulatory Care, 2017-2032 (USD Million)
  • TABLE 203. ASEAN Non-iodinated X-ray Contrast Agents Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 204. GCC Non-iodinated X-ray Contrast Agents Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 205. GCC Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 206. GCC Non-iodinated X-ray Contrast Agents Market Size, by Barium Contrast Media, 2017-2032 (USD Million)
  • TABLE 207. GCC Non-iodinated X-ray Contrast Agents Market Size, by Gadolinium Contrast Media For X-ray, 2017-2032 (USD Million)
  • TABLE 208. GCC Non-iodinated X-ray Contrast Agents Market Size, by Gas Contrast Media, 2017-2032 (USD Million)
  • TABLE 209. GCC Non-iodinated X-ray Contrast Agents Market Size, by Non-iodinated Nanoparticle Contrast Media, 2017-2032 (USD Million)
  • TABLE 210. GCC Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 211. GCC Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 212. GCC Non-iodinated X-ray Contrast Agents Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 213. GCC Non-iodinated X-ray Contrast Agents Market Size, by Angiography, 2017-2032 (USD Million)
  • TABLE 214. GCC Non-iodinated X-ray Contrast Agents Market Size, by Gastrointestinal Imaging, 2017-2032 (USD Million)
  • TABLE 215. GCC Non-iodinated X-ray Contrast Agents Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 216. GCC Non-iodinated X-ray Contrast Agents Market Size, by Ambulatory Care, 2017-2032 (USD Million)
  • TABLE 217. GCC Non-iodinated X-ray Contrast Agents Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 218. European Union Non-iodinated X-ray Contrast Agents Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 219. European Union Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 220. European Union Non-iodinated X-ray Contrast Agents Market Size, by Barium Contrast Media, 2017-2032 (USD Million)
  • TABLE 221. European Union Non-iodinated X-ray Contrast Agents Market Size, by Gadolinium Contrast Media For X-ray, 2017-2032 (USD Million)
  • TABLE 222. European Union Non-iodinated X-ray Contrast Agents Market Size, by Gas Contrast Media, 2017-2032 (USD Million)
  • TABLE 223. European Union Non-iodinated X-ray Contrast Agents Market Size, by Non-iodinated Nanoparticle Contrast Media, 2017-2032 (USD Million)
  • TABLE 224. European Union Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 225. European Union Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 226. European Union Non-iodinated X-ray Contrast Agents Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 227. European Union Non-iodinated X-ray Contrast Agents Market Size, by Angiography, 2017-2032 (USD Million)
  • TABLE 228. European Union Non-iodinated X-ray Contrast Agents Market Size, by Gastrointestinal Imaging, 2017-2032 (USD Million)
  • TABLE 229. European Union Non-iodinated X-ray Contrast Agents Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 230. European Union Non-iodinated X-ray Contrast Agents Market Size, by Ambulatory Care, 2017-2032 (USD Million)
  • TABLE 231. European Union Non-iodinated X-ray Contrast Agents Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 232. BRICS Non-iodinated X-ray Contrast Agents Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 233. BRICS Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 234. BRICS Non-iodinated X-ray Contrast Agents Market Size, by Barium Contrast Media, 2017-2032 (USD Million)
  • TABLE 235. BRICS Non-iodinated X-ray Contrast Agents Market Size, by Gadolinium Contrast Media For X-ray, 2017-2032 (USD Million)
  • TABLE 236. BRICS Non-iodinated X-ray Contrast Agents Market Size, by Gas Contrast Media, 2017-2032 (USD Million)
  • TABLE 237. BRICS Non-iodinated X-ray Contrast Agents Market Size, by Non-iodinated Nanoparticle Contrast Media, 2017-2032 (USD Million)
  • TABLE 238. BRICS Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 239. BRICS Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 240. BRICS Non-iodinated X-ray Contrast Agents Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 241. BRICS Non-iodinated X-ray Contrast Agents Market Size, by Angiography, 2017-2032 (USD Million)
  • TABLE 242. BRICS Non-iodinated X-ray Contrast Agents Market Size, by Gastrointestinal Imaging, 2017-2032 (USD Million)
  • TABLE 243. BRICS Non-iodinated X-ray Contrast Agents Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 244. BRICS Non-iodinated X-ray Contrast Agents Market Size, by Ambulatory Care, 2017-2032 (USD Million)
  • TABLE 245. BRICS Non-iodinated X-ray Contrast Agents Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 246. G7 Non-iodinated X-ray Contrast Agents Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 247. G7 Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 248. G7 Non-iodinated X-ray Contrast Agents Market Size, by Barium Contrast Media, 2017-2032 (USD Million)
  • TABLE 249. G7 Non-iodinated X-ray Contrast Agents Market Size, by Gadolinium Contrast Media For X-ray, 2017-2032 (USD Million)
  • TABLE 250. G7 Non-iodinated X-ray Contrast Agents Market Size, by Gas Contrast Media, 2017-2032 (USD Million)
  • TABLE 251. G7 Non-iodinated X-ray Contrast Agents Market Size, by Non-iodinated Nanoparticle Contrast Media, 2017-2032 (USD Million)
  • TABLE 252. G7 Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 253. G7 Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 254. G7 Non-iodinated X-ray Contrast Agents Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 255. G7 Non-iodinated X-ray Contrast Agents Market Size, by Angiography, 2017-2032 (USD Million)
  • TABLE 256. G7 Non-iodinated X-ray Contrast Agents Market Size, by Gastrointestinal Imaging, 2017-2032 (USD Million)
  • TABLE 257. G7 Non-iodinated X-ray Contrast Agents Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 258. G7 Non-iodinated X-ray Contrast Agents Market Size, by Ambulatory Care, 2017-2032 (USD Million)
  • TABLE 259. G7 Non-iodinated X-ray Contrast Agents Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 260. NATO Non-iodinated X-ray Contrast Agents Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 261. NATO Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 262. NATO Non-iodinated X-ray Contrast Agents Market Size, by Barium Contrast Media, 2017-2032 (USD Million)
  • TABLE 263. NATO Non-iodinated X-ray Contrast Agents Market Size, by Gadolinium Contrast Media For X-ray, 2017-2032 (USD Million)
  • TABLE 264. NATO Non-iodinated X-ray Contrast Agents Market Size, by Gas Contrast Media, 2017-2032 (USD Million)
  • TABLE 265. NATO Non-iodinated X-ray Contrast Agents Market Size, by Non-iodinated Nanoparticle Contrast Media, 2017-2032 (USD Million)
  • TABLE 266. NATO Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 267. NATO Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 268. NATO Non-iodinated X-ray Contrast Agents Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 269. NATO Non-iodinated X-ray Contrast Agents Market Size, by Angiography, 2017-2032 (USD Million)
  • TABLE 270. NATO Non-iodinated X-ray Contrast Agents Market Size, by Gastrointestinal Imaging, 2017-2032 (USD Million)
  • TABLE 271. NATO Non-iodinated X-ray Contrast Agents Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 272. NATO Non-iodinated X-ray Contrast Agents Market Size, by Ambulatory Care, 2017-2032 (USD Million)
  • TABLE 273. NATO Non-iodinated X-ray Contrast Agents Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 274. Global Non-iodinated X-ray Contrast Agents Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 275. United States Non-iodinated X-ray Contrast Agents Market Size, 2017-2032 (USD Million)
  • TABLE 276. United States Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 277. United States Non-iodinated X-ray Contrast Agents Market Size, by Barium Contrast Media, 2017-2032 (USD Million)
  • TABLE 278. United States Non-iodinated X-ray Contrast Agents Market Size, by Gadolinium Contrast Media For X-ray, 2017-2032 (USD Million)
  • TABLE 279. United States Non-iodinated X-ray Contrast Agents Market Size, by Gas Contrast Media, 2017-2032 (USD Million)
  • TABLE 280. United States Non-iodinated X-ray Contrast Agents Market Size, by Non-iodinated Nanoparticle Contrast Media, 2017-2032 (USD Million)
  • TABLE 281. United States Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 282. United States Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 283. United States Non-iodinated X-ray Contrast Agents Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 284. United States Non-iodinated X-ray Contrast Agents Market Size, by Angiography, 2017-2032 (USD Million)
  • TABLE 285. United States Non-iodinated X-ray Contrast Agents Market Size, by Gastrointestinal Imaging, 2017-2032 (USD Million)
  • TABLE 286. United States Non-iodinated X-ray Contrast Agents Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 287. United States Non-iodinated X-ray Contrast Agents Market Size, by Ambulatory Care, 2017-2032 (USD Million)
  • TABLE 288. United States Non-iodinated X-ray Contrast Agents Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 289. Canada Non-iodinated X-ray Contrast Agents Market Size, 2017-2032 (USD Million)
  • TABLE 290. Canada Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 291. Canada Non-iodinated X-ray Contrast Agents Market Size, by Barium Contrast Media, 2017-2032 (USD Million)
  • TABLE 292. Canada Non-iodinated X-ray Contrast Agents Market Size, by Gadolinium Contrast Media For X-ray, 2017-2032 (USD Million)
  • TABLE 293. Canada Non-iodinated X-ray Contrast Agents Market Size, by Gas Contrast Media, 2017-2032 (USD Million)
  • TABLE 294. Canada Non-iodinated X-ray Contrast Agents Market Size, by Non-iodinated Nanoparticle Contrast Media, 2017-2032 (USD Million)
  • TABLE 295. Canada Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 296. Canada Non-iodinated X-ray Contrast Agents Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 297. Canada Non-iodinated X-ray Contrast Agents Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 298. Canada Non-iodinated X-ray Contrast Agents Market Size, by Angiography, 2017-2032 (USD Million)
  • TABLE 299. Canada Non-iodinated X-ray Contrast Agents Market Size, by Gastrointestinal Imaging, 2017-2032 (USD Million)
  • TABLE 300. Canada Non-iodinated X-ray Contrast Agents Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 301. Canada Non-iodinated X-ray Contrast Agents Market Size, by Ambulatory Care, 2017-2032 (USD Million)
  • TABLE 302. Canada Non-iodinated X-ray Contrast Agents Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 303. Mexico Non-iodinated X-ray Contrast Agents Market Size, 2017-2032 (USD Million)
  • TABLE 304. Mexico Non-iodinated X-ray Contrast Agents Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 305. Mexico Non-iodinated X-ray Contrast Agents Market Size, by Barium Contrast Media, 2017-2032 (USD Million)
  • TABLE 306. Mexico Non-iodinated X-ray Contrast Agents Market Size, by Gadolinium Contrast Media For X-ray, 2017-2032 (USD Million)
  • TABLE 307. Mexico Non-iodinated X-ray Contrast Agents Market Size, by Gas Contrast Media, 2017-2032 (USD Million)
  • TABLE 308. Mexico Non-iodinated X-ray Contrast Agents Market Size, by Non-iodinated Nanoparticle Contrast Media, 2017-2032 (USD Million)
  • TABLE 309. Mexico Non-iodinated X-ray Contrast Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)

TA